# EDGAR Filing Document

**Accession Number:** 0001841258
**File Stem:** 0001193125-23-043655
**Filing Date:** 2023-2
**Character Count:** 8974
**Document Hash:** 99832c82d2002cbe874b4614e3e54d26
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-043655.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0001193125-23-043655

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230215

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230221

**DATE AS OF CHANGE**: 20230221

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** European Biotech Acquisition Corp.
- **CENTRAL INDEX KEY:** 0001841258
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40211
- **FILM NUMBER:** 23649324

**BUSINESS ADDRESS:**
- **STREET 1:** EPFL INNOVATION PARK BUILDING
- **CITY:** LAUSANNE
- **STATE:** V8
- **ZIP:** 1015
- **BUSINESS PHONE:** 41 77 976 21 09

**MAIL ADDRESS:**
- **STREET 1:** EPFL INNOVATION PARK BUILDING
- **CITY:** LAUSANNE
- **STATE:** V8
- **ZIP:** 1015

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, DC 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of report (date of earliest event reported): February 15, 2023

------

## EUROPEAN BIOTECH ACQUISITION CORP.

#### (Exact name of registrant as specified in its charter)

------

#### Commission File Number: 001-40211

---

| | |
|:---|:---|
| **Cayman Islands** | **N/A** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(IRS Employer**<br> **Identification No.)** |

---

#### EPFL Innovation Park Building

#### 1015 Lausanne

#### Switzerland

#### (Address of principal executive offices, including zip code)

#### +41 77 976 21 09

#### (Registrant's telephone number, including area code)

#### Johannes Vermeerplein 9

#### 1071 DV Amsterdam, Netherlands

#### (Former address)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 140.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant | EBACU | The NASDAQ Stock Market LLC |
| Class A ordinary shares, par value $0.0001 per share | EBAC | The NASDAQ Stock Market LLC |
| Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 | EBACW | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.03** | **Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.** |

---

On February 15, 2023, European Biotech Acquisition Corp. (the "Company") entered into a loan agreement (the "Loan") with Oculis SA ("Oculis") in the amount of CHF 256,921.68 (the "Loan Amount"), pursuant to which Oculis agreed to pay the Loan Amount on behalf of EBAC for the purpose of increasing the initial share capital of Oculis Holding AG in connection with the Company's previously announced initial business combination.

The Loan bears no interest if repaid prior to March 31, 2023 and otherwise will bear interest equal to the minimal interest published as a safe harbor rule by the Swiss Federal Tax Authorities. The Loan is payable in full in cash on March 31, 2023, unless the Company elects to repay at an earlier date.

A copy of the Loan is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The disclosures set forth in this Item 2.03 are intended to be summaries only and are qualified in their entirety by reference to the Loan.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 10.1 | [Loan Agreement dated February 15, 2023, between European Biotech Acquisition Corp. and Oculis SA](d33167dex101.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 21, 2023

---

| | |
|:---|:---|
| **EUROPEAN BIOTECH ACQUISITION CORP.** | **EUROPEAN BIOTECH ACQUISITION CORP.** |
| By: | /s/ Eduardo Bravo Fernandez de Araoz |
| Name: | Eduardo Bravo Fernandez de Araoz |
| Title: | Chief Executive Officer (Principal Executive Officer) |

---

## Exhibit 10.1

**Exhibit 10.1** 

**Loan Agreement** 

dated 15 February 2023

between

**Oculis SA,** Bâtiment D, EPFL Innovation Park, 1015 Lausanne

(hereinafter "Oculis")

and

**European Biotech Acquisition Corp,** Bâtiment D, EPFL Innovation Park, 1015 Lausanne

(hereinafter "EBAC")

**PREAMBLE** 

On October 17, 2022, EBAC entered into a Business Combination Agreement with Oculis. For the closing of that combination it is advisable, that Oculis Holding AG already has a share capital of CHF 356'821.68. This requires a capital increase from currently CHF 100'0000 by CHF 256'821.68. Oculis SA is willing to lend this amount to EBAC for the purpose of implementing this capital increase on 20 February 2022.

**1.** **GRANT OF LOAN** 

Oculis hereby agrees to grant a loan of CHF 256'821.68 (the "Loan") to EBAC and to transfer such amount on 15 February 2023 to the following blocked bank account of Oculis Holding AG, Bahnhofstrasse 7, 6300 Zug:

---

| | |
|:---|:---|
| Bank: | UBS Switzerland AG, Aeschenvorstadt 1, 4002 Basel |
| IBAN: | CH95 0023 0230 8345 59D7 J |
| Clearing: | 0230 |
| Curreny: | CHF |
| SWIFT / BIC: | UBSWCHZH80A. |

---

**2.** **INTEREST** 

The Loan is interest free if settled prior to 31 March 2023 and otherwise shall bear interest which corresponds to the minimal interest published as safe harbour rule by the Swiss Federal Tax Authorities (see for 2023 the circular letter (*lettre circulaire / Rundschreiben*) No 203 for loans granted to related persons financed out of equity).

------

**3.** **TERM/ DURATION** 

The Loan Agreement has term ending on 31 March 2023 and shall be repaid on the date (or at the election of EBAC also earlier).

**4.** **ASSIGNMENT** 

Neither Party may assign any of its rights under this Agreement to any third party without the prior written consent of the other Party.

**5.** **AMENDMENTS** 

No variation of this Agreement shall be valid unless it is in writing and signed by or on behalf of the Parties to it.

**6.** **SEVERABILITY** 

The unenforceability or nullity of any provision of this Agreement shall not affect the validity or enforceability of any other provisions hereof.

**7.** **GOVERNING LAW AND JURISDICTION** 

This Agreement and all disputes including those concerning any statute of limitations, set-off claims, tort claims and interest claims, shall be governed by the laws of Switzerland excluding its conflict of laws rules.

All disputes arising out of or in connection with this Agreement shall be exclusively submitted to the jurisdiction of the ordinary courts of Lausanne, Switzerland.

15 February 2023

---

| | |
|:---|:---|
| **Oculis SA** | **European Biotech Acquisition Corp** |
| /s/ Riad Sherif | /s/ Eduardo Bravo Fernandez de Araoz |
| Name: Riad Sherif | Name: Eduardo Bravo Fernandez de Araoz |
| Title: CEO | Title: CEO |
| /s/ Sylvia Cheung |  |
| Name: Sylvia Cheung |  |
| Title: CFO |  |

---